Submit a Comment

Perjeta’s APHINITY for HER2+, High-Risk Breast Cancer Patients After Surgery

  1. Kantar Health’s CancerMPact, Treatment Architecture module, 2017.
  2. Jackisch C, et al. Abstract PD5-01, SABCS 2015; Slamon D, et al. Abstract S5-04, SABCS 2015.
  3. Baselga, J, et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med 2012; 366:109-119.
  4. Gianni, L, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. The Lancet Oncology 2016; 17:791–800.
  5. Von Minckwitz, G, et al. APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). Abstract LBA500, ASCO 2017.
  6. Chan, A, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2016; 17:367 – 377.

Post a Comment

Your email is never shared. Required fields are marked *